China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.
Joint Development and Commercialization of Intratumoral Immunotherapies
Eucure and Syncromune have agreed to jointly develop and commercialize intratumoral immunotherapies based on Syncromune’s proprietary Syncrovax technology. Syncromune will hold exclusive development and commercialization rights to the intratumoral immunotherapy composed of YH002 and other active pharmaceutical ingredients (APIs) to be applied to Syncrovax therapy.
YH002: A Monoclonal Antibody Targeting OX40
YH002 is a monoclonal antibody (mAb) targeting OX40, which is under development as a SYNC-T-based intratumoral immunotherapy combined with other clinical antibodies. This approach aims to leverage the potential of intratumoral immunotherapies for treating cancer.
SYNC-T: Syncromune’s Innovative Technology Platform
Syncromune is developing SYNC-T, a disruptive personalized in situ technology platform designed to educate T cells and activate the immune system to treat previously untreatable metastatic solid tumors. SYNC-T utilizes a combination of tumor activation and targeted delivery methods to synchronize the spatiotemporal release of tumor antigens with the functional activation of immune cells, offering a new frontier in cancer immunotherapy.-Fineline Info & Tech
